Mesoblast Says Fiscal Q1 Cell Therapy Sales Rises More Than Tenfold

MT Newswires Live

Oct 20, 2025

Mesoblast (ASX:MSB) reported cell therapy products revenue of $20.6 million for the quarter ended Sept. 30, more than tenfold from last year, according to a Monday Australian bourse filing.

The company also said it intends to start a pivotal study of its drug Ryoncil, in adults with severe in adults with severe steroid-refractory acute graft-versus-host disease (SR-aGvHD), the filing said.

Ryoncil is the company's mesenchymal stromal cell product, approved by the US Food and Drug Administration, to treat SR-aGvHD in children under age 12.

Shares of the company rose past 2% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576688865"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576688865\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576688865?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576688865","market":"sg","top_or_hot":-1,"title":"Mesoblast Says Fiscal Q1 Cell Therapy Sales Rises More Than Tenfold","media":"MT Newswires Live","content":"<html><body><p> Mesoblast (ASX:MSB) reported cell therapy products revenue of $20.6 million for the quarter ended Sept. 30, more than tenfold from last year, according to a Monday Australian bourse filing.</p><p>The company also said it intends to start a pivotal study of its drug Ryoncil, in adults with severe in adults with severe steroid-refractory acute graft-versus-host disease (SR-aGvHD), the filing said.</p><p>Ryoncil is the company's mesenchymal stromal cell product, approved by the US Food and Drug Administration, to treat SR-aGvHD in children under age 12.</p><p>Shares of the company rose past 2% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mesoblast Says Fiscal Q1 Cell Therapy Sales Rises More Than Tenfold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMesoblast Says Fiscal Q1 Cell Therapy Sales Rises More Than Tenfold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-20 09:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mesoblast (ASX:MSB) reported cell therapy products revenue of $20.6 million for the quarter ended Sept. 30, more than tenfold from last year, according to a Monday Australian bourse filing.</p><p>The company also said it intends to start a pivotal study of its drug Ryoncil, in adults with severe in adults with severe steroid-refractory acute graft-versus-host disease (SR-aGvHD), the filing said.</p><p>Ryoncil is the company's mesenchymal stromal cell product, approved by the US Food and Drug Administration, to treat SR-aGvHD in children under age 12.</p><p>Shares of the company rose past 2% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MESO","symbol_name":"Mesoblast Limited","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576688865","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576688865","pubTimestamp":1760923289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mesoblast  reported cell therapy products revenue of $20.6 million for the quarter ended Sept. 30, more than tenfold from last year, according to a Monday Australian bourse filing.The company also said it intends to start a pivotal study of its drug Ryoncil, in adults with severe in adults with severe steroid-refractory acute graft-versus-host disease , the filing said.Ryoncil is the company's mesenchymal stromal cell product, approved by the US Food and Drug Administration, to treat SR-aGvHD in children under age 12.Shares of the company rose past 2% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MESO":"Mesoblast Limited"},"translate_title":"Mesoblast表示第一财季细胞疗法销售额增长十倍以上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MESO":1.5},"content_text":"Mesoblast (ASX:MSB) reported cell therapy products revenue of $20.6 million for the quarter ended Sept. 30, more than tenfold from last year, according to a Monday Australian bourse filing.The company also said it intends to start a pivotal study of its drug Ryoncil, in adults with severe in adults with severe steroid-refractory acute graft-versus-host disease (SR-aGvHD), the filing said.Ryoncil is the company's mesenchymal stromal cell product, approved by the US Food and Drug Administration, to treat SR-aGvHD in children under age 12.Shares of the company rose past 2% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}